Angiotensin blockade in XXXX @entity1 decreases insulin resistance-associated low-grade @entity32 .

@entity1 @entity32 @entity650 @entity6 @entity2178 @entity1564 @entity2842 @entity2412 @entity209 @entity3918 @entity1851
BACKGROUND: Insulin-resistant states, such as @entity209 and @entity6 ( @entity6 ), have been associated with chronic low-grade systemic @entity32 . Elevated levels of @entity650 ( @entity650 ), monocyte chemoattractant protein ( @entity2842 ) and @entity1851 (hs-CRP), are found in @entity1 with @entity2412 . @entity2178 ( @entity2178 ), a potent vasopressor, seems to regulate also the expression of the above inflammatory mediators acting as proinflammatory cytokine. In this study, we examined the effects of @entity1564 , an angiotensin receptror blocker, in the chronic low-grade @entity32 observed in @entity3918 2. MATERIALS AND METHODS: Seventeen @entity1 with @entity6 of <5years duration were recruited for the study. @entity1 received 4mg of @entity1564 , an angiotensin receptor blocker, for 6months. Blood levels of @entity650 , @entity2842 , hs-CRP and other inflammatory indices were measured before and at the end of @entity1564 administration. RESULTS: At the end of treatment with @entity1564 , @entity650 levels decreased significantly (P<0  05). Serum levels of @entity2842 and hs-CRP showed a trend for significant decrease with treatment (P<0  08 and P<0  09, respectively). Statistically significant correlations were found between hs-CRP and @entity2842 (r=0  623, P<   0  05), @entity650 and @entity2842 (r=0  703, P<0  05) and TRT and @entity2842 (r=0  752, P<0  05), before but not at the end of @entity1564 administration. CONCLUSIONS: @entity1564 could decrease the low-grade @entity32 of type 2 @entity3918 as shown by the decrease of inflammatory mediators. Thus, angiotensin receptor blockers could be useful for treating @entity1 with @entity6 not only for their antihypertensive capacity but also for their anti-inflammatory actions.
